Literature DB >> 6415113

von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.

J L Miller, J M Kupinski, A Castella, Z M Ruggeri.   

Abstract

Platelet-type von Willebrand disease (vWD) and pseudo-vWD are two recently described intrinsic platelet defects characterized by enhanced ristocetin-induced agglutination in platelet-rich plasma. A similar finding is also typical of type IIB vWD, where it has been related to a von Willebrand factor (vWF) rather than a platelet abnormality. Platelet aggregation induced by unmodified human vWF in the absence of other stimuli has been reported in pseudo-vWD. In this study we demonstrate that vWF induces aggregation in platelet-type but not type IIB vWD. Aggregation is observed when normal plasma cryoprecipitate or purified vWF are added to platelet-rich plasma. Cryoprecipitate also aggregates washed platelets, although at higher concentrations than required for platelet-rich plasma. Purified vWF, however, induces significant aggregation of washed platelets only when plasma is added. EDTA inhibits vWF-induced aggregation. Its effect can be overcome by calcium but much less effectively by magnesium ions. Unstimulated platelets in platelet-rich plasma from patients with platelet-type but not type IIB vWD bind 125I-vWF in a specific and saturable manner. All different sized multimers of vWF become associated with platelets. Both aggregation and binding exhibit a similar vWF concentration dependence, suggesting that a correlation exists between these two events. Removal of ADP by appropriate consuming systems is without effect upon such binding or upon vWF-induced aggregation. Thrombin-induced 125I-vWF binding to washed platelets is normal in platelet-type as well as type IIB vWD. These results demonstrate that a specific binding site for unmodified human vWF is exposed on unstimulated platelets in platelet-type vWD. The relatively high vWF concentrations required for aggregation and binding may explain the lack of significant in vivo aggregation and thrombocytopenia in these patients. Moreover, these studies provide additional evidence that platelet-type and type IIB vWD are different diseases with distinct pathogeneses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6415113      PMCID: PMC370441          DOI: 10.1172/JCI111112

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

Review 2.  Membrane receptors and hormone action.

Authors:  P Cuatrecasas; M D Hollenberg
Journal:  Adv Protein Chem       Date:  1976

3.  Metabolism and function of human platelets washed by albumin density gradient separation.

Authors:  P N Walsh; D C Mills; J G White
Journal:  Br J Haematol       Date:  1977-06       Impact factor: 6.998

4.  Factor VIII-related properties in platelets from patients with von Willebrand's disease.

Authors:  Z M Ruggeri; P M Mannucci; R Bader; T Barbui
Journal:  J Lab Clin Med       Date:  1978-01

5.  Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis.

Authors:  H J Weiss; T B Tschopp; H R Baumgartner; I I Sussman; M M Johnson; J J Egan
Journal:  Am J Med       Date:  1974-12       Impact factor: 4.965

6.  Aggregation of human platelets by purified porcine and bovine antihaemophilic factor.

Authors:  C D Forbes; C R Prentice
Journal:  Nat New Biol       Date:  1973-01-31

7.  Ristocetin--a new tool in the investigation of platelet aggregation.

Authors:  M A Howard; B G Firkin
Journal:  Thromb Diath Haemorrh       Date:  1971-10-31

8.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

9.  Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates.

Authors:  J Newman; A J Johnson; M H Karpatkin; S Puszkin
Journal:  Br J Haematol       Date:  1971-07       Impact factor: 6.998

10.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

View more
  15 in total

1.  Hemostasis Laboratory: Assays for Platelet Function and Von Willebrand Disease.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-09       Impact factor: 2.300

Review 2.  Laboratory testing for von Willebrand disease: toward a mechanism-based classification.

Authors:  Richard Torres; Yuri Fedoriw
Journal:  Clin Lab Med       Date:  2009-06       Impact factor: 1.935

3.  Mimotope/anti-mimotope probing of structural relationships in platelet glycoprotein Ib alpha.

Authors:  J L Miller; V A Lyle
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

Review 4.  Diagnostic approach to von Willebrand disease.

Authors:  Christopher Ng; David G Motto; Jorge Di Paola
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

5.  Adhesive properties of the isolated amino-terminal domain of platelet glycoprotein Ibalpha in a flow field.

Authors:  P Marchese; E Saldívar; J Ware; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

6.  Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease.

Authors:  J L Miller; D Cunningham; V A Lyle; C N Finch
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

7.  Structural implications of the substitution of Val for Met at residue 239 in the alpha chain of human platelet glycoprotein Ib.

Authors:  M R Pincus; R P Carty; J L Miller
Journal:  J Protein Chem       Date:  1994-10

8.  Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors.

Authors:  L De Marco; M Mazzuccato; M Grazia Del Ben; U Budde; A B Federici; A Girolami; Z M Ruggeri
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

9.  von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure.

Authors:  L Holmberg; J A Dent; R Schneppenheim; U Budde; J Ware; Z M Ruggeri
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

10.  Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib alpha fragment.

Authors:  M Murata; S R Russell; Z M Ruggeri; J Ware
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.